are initiated during or after the first trimester. 4 For example, the odds ratio (OR) of risk of cardiovascular malformations attributable to administration of angiotensin-converting enzyme inhibitors during the first trimester amounts to 1.9 [95% confidence interval (CI) 0.5-7.2] and the corresponding OR attributable to other hypertensive classes (including b-adrenergic blockers, calcium channel blockers and diuretics) amounts to 1.7 (95% CI 1.1-2.8) during that period. The OR of the risk of pulmonary valve stenosis for anti-hypertensive drugs initiated during the first trimester amounts to 2.6 (95% CI 1.3-5.4), the corresponding OR for Ebstein malformation being 11.4 (95% CI 2.8-34.1), for coarctation of the aorta being 3.0 (95% CI 1.3-6.6) and for secundum atrial defects being 2.4 (95% CI 1.3-4.4). The OR of risk of anti-hypertensive drug-related pulmonary valve stenosis for treatment initiated after the first trimester amounts to 2.4 (95% CI 1.1-5.4), the corresponding OR for perimembranous ventricular septal defect being 2.3 (95% CI 1.2-4.6) and for secundum atrial septal defect being 2.4 (95% CI 1.3-4.4). 4 Although a more intensive haemodialfiltration protocol (including haemodialfiltration at least 6 times a week) appears to be the one that conferred a favourable outcome in five pregnant women with pre-treatment creatinine in the range 3.5-7.3 mg/dl (median 5.4 mg/dl), who subsequently gave birth to offspring who developed into healthy infants, the effect of that regime on blood pressure was not documented. 5 Accordingly, the remit of future research should include evaluation of the intensity of haemodialysis which best maintains maternal blood pressure in an optimum range and also mitigates the risk of foetal distress attributable to hypotensive episodes. That research would also provide an answer to the vexed question of what the 'goal' blood pressure ought to be in the pregnant hypertensive patient who is on haemodialysis. Furthermore, meta-analysis has shown that vitamin D supplementation reduces the risk of falls by420% among elderly ambulatory or institutionalized individuals. 9 It is disturbing that vitamin D insufficiency and deficiency have been increasing in the USA over the past decade. 10 As a result, a majority of the population is now vitamin D insufficient and this state is even more prevalent in darker skinned individuals. 10 Similar trends have been seen in European populations. 11 Optimal serum 25(OH)D levels for lower extremity function are 40 ng/ml and higher. 12 Since a majority of individuals are vitamin D insufficient, vitamin D supplementation will be necessary to achieve these levels. Oral supplementation with daily cholecalciferol (vitamin D 3 ) will be adequate to correct most insufficiency states 13 and toxicity is rare when doses do not exceed 10 000 IU daily 14 or serum levels are not4100 ng/ml. 15 Of note, 1000 IU of vitamin D 3 increases serum 25(OH)D levels by 7 ng/ml. 16 In summary, it is important for elderly individuals to maintain adequate vitamin D levels for proper muscle performance and fall prevention. The study of Scott and colleagues 1 suggest that maintaining vitamin D adequacy even becomes more critical in the elderly treated with statin therapy. Therefore, we advise measuring serum 25(OH)D levels prior to the use of statins and periodically during treatment, and maintaining levels 440 ng/ml with appropriate supplementation. Finally, statin therapy is expensive and of questionable benefit in the elderly, particularly in the primary prevention of cardiovascular disease, 17 but, vitamin D supplementation is inexpensive and its potential benefits are huge in this population. 
